These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eyre TA; Khan D; Hall GW; Collins GP Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435 [TBL] [Abstract][Full Text] [Related]
7. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. Shustov A; Soma L Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608 [TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma. Foyil KV; Bartlett NL Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951 [TBL] [Abstract][Full Text] [Related]
10. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048 [TBL] [Abstract][Full Text] [Related]
11. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770 [TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Querfeld C; Khan I; Mahon B; Nelson BP; Rosen ST; Evens AM Oncology (Williston Park); 2010 Jun; 24(7):574-87. PubMed ID: 20669794 [TBL] [Abstract][Full Text] [Related]
13. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999 [TBL] [Abstract][Full Text] [Related]
14. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD; Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450 [TBL] [Abstract][Full Text] [Related]
15. Qiu L; Tang G; Li S; Vega F; Lin P; Wang SA; Wang W; Iyer SP; Malpica L; Miranda RN; Konoplev S; Tang Z; Fang H; Medeiros LJ; Xu J Haematologica; 2023 Jun; 108(6):1604-1615. PubMed ID: 36453104 [TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma. Wang X; Wu J; Zhang M Hematology; 2019 Dec; 24(1):440-445. PubMed ID: 31072226 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993 [TBL] [Abstract][Full Text] [Related]
18. Primary anaplastic large cell lymphoma in the dura of the brain: case report and prediction of a favorable prognosis. Kim MK; Cho CH; Sung WJ; Ryoo HM; Lee HJ; Youn SW; Park KK Int J Clin Exp Pathol; 2013; 6(8):1643-51. PubMed ID: 23923083 [TBL] [Abstract][Full Text] [Related]
19. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL. Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y Front Immunol; 2024; 15():1346001. PubMed ID: 38375471 [TBL] [Abstract][Full Text] [Related]
20. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. Pulitzer M; Ogunrinade O; Lin O; Steinherz P J Cutan Pathol; 2015 Mar; 42(3):182-187. PubMed ID: 25404214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]